SG Americas Securities LLC Has $218,000 Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

SG Americas Securities LLC lowered its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 94.9% during the fourth quarter, Holdings Channel reports. The fund owned 3,043 shares of the biopharmaceutical company’s stock after selling 56,396 shares during the quarter. SG Americas Securities LLC’s holdings in Intra-Cellular Therapies were worth $218,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in ITCI. JPMorgan Chase & Co. raised its holdings in shares of Intra-Cellular Therapies by 11.7% during the first quarter. JPMorgan Chase & Co. now owns 157,144 shares of the biopharmaceutical company’s stock valued at $9,615,000 after acquiring an additional 16,454 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Intra-Cellular Therapies by 5.2% during the first quarter. Bank of New York Mellon Corp now owns 385,508 shares of the biopharmaceutical company’s stock valued at $23,591,000 after acquiring an additional 18,999 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Intra-Cellular Therapies during the first quarter valued at approximately $349,000. PNC Financial Services Group Inc. raised its holdings in shares of Intra-Cellular Therapies by 25.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,909 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 1,204 shares during the period. Finally, Natixis Advisors L.P. raised its holdings in shares of Intra-Cellular Therapies by 71.3% during the first quarter. Natixis Advisors L.P. now owns 18,165 shares of the biopharmaceutical company’s stock valued at $1,112,000 after acquiring an additional 7,558 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ITCI shares. Cantor Fitzgerald restated an “overweight” rating and set a $101.00 price target on shares of Intra-Cellular Therapies in a report on Friday, February 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Bank of America boosted their price objective on shares of Intra-Cellular Therapies from $74.00 to $82.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Canaccord Genuity Group lowered their price objective on shares of Intra-Cellular Therapies from $101.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday, February 23rd. Finally, Mizuho boosted their price objective on shares of Intra-Cellular Therapies from $76.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and an average price target of $81.42.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock opened at $65.88 on Friday. Intra-Cellular Therapies, Inc. has a 52-week low of $45.50 and a 52-week high of $76.11. The stock has a market cap of $6.38 billion, a price-to-earnings ratio of -45.12 and a beta of 1.02. The firm has a fifty day moving average of $69.03 and a 200-day moving average of $63.32.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The company had revenue of $132.10 million during the quarter, compared to analysts’ expectations of $135.97 million. During the same quarter in the prior year, the company posted ($0.45) EPS. The business’s revenue was up 50.3% on a year-over-year basis. On average, sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.65 earnings per share for the current year.

Insider Transactions at Intra-Cellular Therapies

In other news, EVP Suresh K. Durgam sold 6,450 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.56, for a total value of $429,312.00. Following the sale, the executive vice president now owns 16,170 shares of the company’s stock, valued at approximately $1,076,275.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Intra-Cellular Therapies news, EVP Suresh K. Durgam sold 6,450 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the sale, the executive vice president now owns 16,170 shares of the company’s stock, valued at approximately $1,076,275.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Halstead sold 7,345 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.97, for a total transaction of $484,549.65. Following the completion of the transaction, the executive vice president now directly owns 19,803 shares in the company, valued at approximately $1,306,403.91. The disclosure for this sale can be found here. In the last quarter, insiders have sold 311,765 shares of company stock valued at $20,860,487. 3.40% of the stock is owned by insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.